0000899243-16-021416.txt : 20160602 0000899243-16-021416.hdr.sgml : 20160602 20160602061659 ACCESSION NUMBER: 0000899243-16-021416 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160601 FILED AS OF DATE: 20160602 DATE AS OF CHANGE: 20160602 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REATA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001358762 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113651945 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2801 GATEWAY DRIVE SUITE 150 CITY: IRVING STATE: TX ZIP: 75063 BUSINESS PHONE: 972-865-2206 MAIL ADDRESS: STREET 1: 2801 GATEWAY DRIVE SUITE 150 CITY: IRVING STATE: TX ZIP: 75063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meyer Colin John CENTRAL INDEX KEY: 0001662392 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37785 FILM NUMBER: 161691071 MAIL ADDRESS: STREET 1: C/O REATA PHARMACEUTICALS, INC. STREET 2: 2801 GATEWAY DR. SUITE 150 CITY: IRVING STATE: TX ZIP: 75063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-06-01 0 0001358762 REATA PHARMACEUTICALS INC RETA 0001662392 Meyer Colin John 2801 GATEWAY DRIVE, SUITE 150 IRVING TX 75063 0 1 0 0 See Remarks Class A common stock 2016-06-01 4 C 0 10172 A 10172 D Class A common stock 2016-06-01 4 P 0 10000 11.00 A 20172 D Class B common stock 2016-06-01 4 C 0 10172 0.00 D Class A common stock 10172 113985 D The Class B common stock is convertible into Class A common stock on a one-for-one basis (a) at the holder's election at any time after the date that is six months following the date of the closing of the initial public offering of the company's Class A common stock, (b) at the holder's election prior to that time subject to certain conditions, or (c) at the option of the company's board of directors, in its sole discretion, at any time or multiple times from time to time on or before the closing of the initial public offering. The conversion right of the Class B common stock has no expiration date. Chief Medical Officer and Vice President, Product Development /s/ Michael D. Wortley, attorney-in-fact 2016-06-01